Form D · Biotechnology
AveXis, Inc.
Bannockburn, IL · CIK 0001652923
Offering snapshot reported Sep 17, 2015 · SEC filing
- Reported sold
- $65M Offering amount: $65M
- Investors reported
- 27 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Sep 3, 2015 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 17, 2015 | Initial | $65,000,020 | No comparison | 27 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-247819
Source: Form D, filed Sep 17, 2015. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Thomas Dee | Executive |
| John D. Harkey | Director |
| Brian Kaspar | Director, Executive |
| Andrew F. Knudten | Executive |
| Bong Koh | Director |
| Jonathan Leff | Director |
| James L'italien | Executive |
| Paul Manning | Director |
| Sukumar Nagendran | Executive |
| Sean Nolan | Director, Executive |
| Carole Nuechterlain | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
2275 Half Day Road Suite 160
Bannockburn, IL, 60015
Bannockburn, IL, 60015